U.S. Communications Stock News

NasdaqGM:RANI
NasdaqGM:RANIPharmaceuticals

Rani Therapeutics (RANI): Valuation in Focus After Landmark Chugai Deal and Breakthrough Clinical Data

Rani Therapeutics Holdings (RANI) just made headlines with a new licensing agreement with Chugai Pharmaceutical. This deal brings over $1 billion in potential revenue for its RaniPill technology and boosts its financial flexibility. See our latest analysis for Rani Therapeutics Holdings. Momentum around Rani Therapeutics Holdings has accelerated sharply, with a 1-month share price return of nearly 400% and year-to-date gains over 70%. This reflects investor excitement after its Chugai deal...